Every publicly-traded stock’s price is connected to the earning and increase in earnings. In rare times the share price of a particular company plummets because of the drastic change in public sentiment. Fear, safety scares, scandals, moral revulsion, and disgust are enough to send the stock into free fall.
Recent reports say that while Pfizer forecasts a $54 billion year in sales for the fiscal year of 2022, the share price may experience price action downwards because of the unfavorable safety data.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
Revenues may dry up if many people refuse Pfizer’s products.
Once the reports pass from the realm of independent journalism to the MSM sphere, negative public sentiment will follow.
This is what we know:
Zero Hedge reported:
Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
The Epoch Times added:
The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in 2022 as demand for the products continues.
Those numbers are based on contracts signed or close to being signed as of late January, Pfizer said.